<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312542</url>
  </required_header>
  <id_info>
    <org_study_id>DENT-2020-28624</org_study_id>
    <nct_id>NCT04312542</nct_id>
  </id_info>
  <brief_title>Systemic Markers of Inflammation: 9- and 12-Month Follow-Up Post Non-Surgical Periodontal Therapy</brief_title>
  <official_title>Systemic Markers of Inflammation: 9- and 12-Month Follow-Up Post Non-Surgical Periodontal Therapy With and Without Minocycline HCl Microspheres, 1mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to determine the amount of three systemic markers of&#xD;
      inflammation: 1) Hemoglobin A1c (Hgb A1c, 2) High Sensitivity C-Reactive Protein (hsCRP), and&#xD;
      3) Haptoglobin (Hp) at 9 and 12 month follow-up post scaling and rootplaning (SRP) with and&#xD;
      without minocycline HCl microspheres, 1 mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants from a randomized controlled clinical trial approved by the University of&#xD;
      Minnesota (UMN) Institutional Review Board (IRB) STUDY00004876 and registered on&#xD;
      ClinicalTrials.gov (NCT03762915) identifying the effects of SRP with and without minocycline&#xD;
      HCl microspheres, 1 mg on periodontal pathogens and systemic inflammatory markers in the&#xD;
      blood serum will be invited to participate in this 9 and 12 month follow-up study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Hemoglobin A1C Concentration</measure>
    <time_frame>9 months</time_frame>
    <description>Serum hemoglobin A1C (hbA1c) concentration will be measured using enzyme-linked immunosorbant assay (ELISA) and reported in standard clinical units (percent glycolated erythrocytes).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Hemoglobin A1C Concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Serum hemoglobin A1C (hbA1c) concentration will be measured using enzyme-linked immunosorbant assay (ELISA) and reported in standard clinical units (percent glycolated erythrocytes).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration</measure>
    <time_frame>9 months</time_frame>
    <description>Serum high sensitivity CRP concentration will be measured using enzyme-linked immunosorbant assay (ELISA) and reported in units of mg/l.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Serum high sensitivity CRP concentration will be measured using enzyme-linked immunosorbant assay (ELISA) and reported in units of mg/l.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Haptoglobin Concentration</measure>
    <time_frame>9 months</time_frame>
    <description>Serum haptoglobin concentration will be measured using enzyme-linked immunosorbant assay (ELISA) and reported in units of mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Haptoglobin Concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Serum haptoglobin concentration will be measured using enzyme-linked immunosorbant assay (ELISA) and reported in units of mg/dl.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>SRP</condition>
  <condition>Minocycline HCl Microspheres</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>SRP with minocycline HCl microspheres</arm_group_label>
    <description>Participants in this cohort received the intervention of minocycline HCl microspheres, 1 mg in the interventional phase of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP without minocycline HCl microspheres</arm_group_label>
    <description>Participants in this cohort did not have minocycline HCl microspheres, 1 mg administered during the interventional phase of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Measurement of Biomarkers</intervention_name>
    <description>Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.</description>
    <arm_group_label>SRP with minocycline HCl microspheres</arm_group_label>
    <arm_group_label>SRP without minocycline HCl microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from a randomized controlled clinical trial approved by the University of&#xD;
        Minnesota (UMN) Institutional Review Board (IRB) STUDY00004876 and registered on&#xD;
        ClinicalTrials.gov (NCT03762915) identifying the effects of SRP with and without&#xD;
        minocycline HCl microspheres, 1 mg on periodontal pathogens and systemic inflammatory&#xD;
        markers in the blood serum will be invited to participate in this 9 and 12 month follow-up&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Participated in interventional phase of the trial STUDY00004876&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to comply with study protocol&#xD;
&#xD;
          -  Cigarette use within the last year&#xD;
&#xD;
          -  â‰¥2 weeks of antibiotic use in the past three months or antibiotic use in the last six&#xD;
             weeks.&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or unsure of pregnancy status (self- reported)&#xD;
&#xD;
          -  Diagnosed cardiac conditions (cardiovascular disease (CVD) or atherosclerotic vascular&#xD;
             disease (ASVD) including coronary heart disease, cerebrovascular disease, and&#xD;
             peripheral artery disease, myocardial infarction, stroke, stable or unstable angina,&#xD;
             transient ischemic attack, or coronary or other arterial revascularization&#xD;
&#xD;
          -  Have any uncontrolled medical condition or immunocompromised that may impact the study&#xD;
             (uncontrolled diabetes HbA1c &gt; 7, HIV, etc.)&#xD;
&#xD;
          -  Any medication that may impact periodontal conditions (Phenytoin, calciumantagonists,&#xD;
             cyclosporin, warfarin, or NSAIDS)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle B Arnett, RDH, BS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

